PerpEquities

Laporan laba rugi AbCellera Biologics Inc. (ABCL)

NASDAQ · Healthcare · Biotechnology · Karyawan: 562 · CEO: Carl Hansen

Harga
$12,27 -6,19%
Kapitalisasi pasar
$3,98 M
Nilai perusahaan
$3,99 M
Laporan terakhir
Q2 '26 diajukan 2026-08-05
Laporan berikutnya
2026-11-09

AbCellera Biologics Inc. (ABCL) untuk Q2 '26: pendapatan $4,05 jt (-76,3% yoy), laba operasional -$62,8 jt (-1.550,0% dari pendapatan), laba bersih -$55,4 jt. Dalam empat kuartal terakhir pendapatan mencapai $66,2 jt.

Laporan laba rugi

Laporan laba rugiTrenQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Pendapatan$6,6 jt$9,18 jt$9,95 jt$7,32 jt$6,51 jt$5,05 jt$4,24 jt$17,1 jt$8,96 jt$44,9 jt$8,32 jt$4,05 jt
Beban pokok pendapatan$0$0$0$0$0$0$0$0$0$7,92 jt$8,66 jt$0
Laba kotor$6,6 jt$9,18 jt$9,95 jt$7,32 jt$6,51 jt$5,05 jt$4,24 jt$17,1 jt$8,96 jt$36,9 jt-$340 rb$4,05 jt
Riset & pengembangan$37,9 jt$48,6 jt$39,3 jt$40,9 jt$41 jt$46,1 jt$42,5 jt$39,2 jt$55 jt$50,1 jt$46,7 jt$46 jt
Penjualan & pemasaran$3,47 jt$3,1 jt$3,37 jt$3,14 jt$3,14 jt$3,14 jt$2,84 jt$3,01 jt$2,91 jt$0$0$0
Umum & administrasi$14,4 jt$16 jt$17,4 jt$20,2 jt$19,1 jt$16 jt$16,2 jt$19 jt$22,1 jt$0$0$0
Beban operasional lainnya$5,74 jt$7,54 jt$4,84 jt$36,5 jt$36,9 jt$12,6 jt$5,33 jt$5,47 jt$5,25 jt$0$0$6,99 jt
Beban operasional$61,5 jt$75,2 jt$64,8 jt$101 jt$100 jt$77,8 jt$66,9 jt$66,7 jt$85,2 jt$65,5 jt$57,2 jt$66,8 jt
Laba operasional-$54,9 jt-$66,1 jt-$54,9 jt-$93,5 jt-$93,7 jt-$72,8 jt-$62,7 jt-$49,6 jt-$76,3 jt-$28,6 jt-$57,5 jt-$62,8 jt
Pendapatan bunga$10,7 jt$11 jt$10,4 jt$9,8 jt$9,6 jt$8,67 jt$8,05 jt$7,59 jt$6,77 jt$5,92 jt$3,64 jt$0
Pendapatan non-operasional lainnya (keuntungan investasi, kurs ...)-$2,83 jt-$3,38 jt-$3,28 jt-$3,31 jt-$3,49 jt-$3,54 jt-$4,15 jt-$3,69 jt-$2,73 jt-$9,08 jt-$7,98 jt-$3,81 jt
Total pendapatan non-operasional$15,6 jt$17,5 jt$12,1 jt$45,3 jt$31 jt$25,9 jt$9,68 jt$13,2 jt$7,51 jt$9,08 jt$7,98 jt$3,81 jt
Laba sebelum pajak-$39,3 jt-$48,6 jt-$42,7 jt-$48,2 jt-$62,6 jt-$46,8 jt-$53 jt-$36,3 jt-$68,8 jt-$19,5 jt-$49,5 jt-$59 jt
Pajak penghasilan-$10,7 jt-$1,45 jt-$2,14 jt-$11,3 jt-$11,5 jt-$12,6 jt-$7,36 jt-$1,62 jt-$11,6 jt-$10,6 jt-$6,37 jt-$3,54 jt
Laba bersih-$28,6 jt-$47,2 jt-$40,6 jt-$36,9 jt-$51,1 jt-$34,2 jt-$45,6 jt-$34,7 jt-$57,1 jt-$8,95 jt-$43,2 jt-$55,4 jt
EPS (dasar)-$0,10-$0,16-$0,14-$0,13-$0,17-$0,12-$0,15-$0,12-$0,19-$0,03-$0,14-$0,18
EPS (dilusian)-$0,10-$0,16-$0,14-$0,13-$0,17-$0,12-$0,15-$0,12-$0,19-$0,03-$0,14-$0,18
Saham (dasar, rata-rata tertimbang)289 jt291 jt293 jt294 jt295 jt295 jt298 jt299 jt299 jt299 jt303 jt306 jt
Saham (dilusian, rata-rata tertimbang)289 jt291 jt293 jt294 jt295 jt295 jt298 jt299 jt299 jt299 jt303 jt306 jt
Depresiasi & amortisasi$7,41 jt$9,11 jt$6,77 jt$38 jt$38,3 jt$13,9 jt$6,61 jt$7,06 jt$7,24 jt$7,92 jt$8,66 jt$8,78 jt
EBITDA-$44,7 jt-$53,6 jt-$44,9 jt-$52,1 jt-$51,9 jt-$55,3 jt-$51,9 jt-$38,8 jt-$66,3 jt-$11,6 jt-$40,9 jt-$50,2 jt

Distandardisasi dari laporan perusahaan; arus keluar dan biaya mempertahankan tanda yang dilaporkan penyedia. Arahkan kursor ke periode untuk melihat tanggal berakhirnya. Jumlah dalam USD.

Pendapatan, laba operasional, dan pertumbuhan

kuartalan

Margin

kuartalan

Biaya sebagai % pendapatan

kuartalan

Laporan lainnya

Sumber

Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30

Data per 2026-11-02